title: Erythropoietin in the critically ill: do we ask the right questions?
abstract: There is a plethora of experimental data on the potential therapeutic benefits of recombinant human erythropoietin (rhEPO) and its synthetic derivatives in critical care medicine, in particular in ischemia/reperfusion injury. Most of the recent clinical trials have not shown clear benefits, and, in some patients, EPO-aggravated morbidity and mortality was even reported. Treatment with rhEPO has been successfully used in patients with anemia resulting from chronic kidney disease, but even a subset of this patient population does not adequately respond to rhEPO therapy. The following viewpoint uses rhEPO as an example to highlight the possible pitfalls in current practice using young healthy animals for the evaluation of therapies to treat patients of variable age and underlying chronic co-morbidity.
authors.forename: Oscar
authors.initials: O
authors.lastname: McCook
authors.forename: Michael
authors.initials: M
authors.lastname: Georgieff
authors.forename: Angelika
authors.initials: A
authors.lastname: Scheuerle
authors.forename: Peter
authors.initials: P
authors.lastname: Möller
authors.forename: Christoph
authors.initials: C
authors.lastname: Thiemermann
authors.forename: Peter
authors.initials: P
authors.lastname: Radermacher
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy*; D000818:Animals; D002986:Clinical Trials as Topic; D016638:Critical Illness; D004351:Drug Resistance; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D023421:Models, Animal; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000150:complications; D015427:Reperfusion Injury / Q000517:prevention & control*
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin